ClearTrial Clinical Trial Planning Experts to Speak at CBI Global Clinical Trial Forecasting & Budgeting Conference
ClearTrial Senior Directors of Clinical Services Kristin Lucas and Deirdre BeVard will offer practical guidelines for accurately forecasting costs and improving accruals and contract management for global clinical trials.
Chicago, IL (PRWEB) September 8, 2008
ClearTrial, a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Kristin Lucas and Deirdre BeVard, ClearTrial Senior Directors of Clinical Services, will speak at the CBI Forecasting & Budgeting for Global Clinical Trials conference at the Crowne Plaza Main Line Hotel in Philadelphia, September 25-26, 2008.
Lucas will present "Opportunities for Cost Savings in New and Emerging Markets," examining the promise and pitfalls of conducting trials in markets such as China, India, Japan, and South America. She will point out areas where often promised operational benefits and cost savings are real, as well as where there are often overlooked increases in time and costs. In addition, Lucas will provide proven methods to protect against operational surprises.
Attendees will discover:
Forecasting trials in new and emerging markets -- where are the most cost-effective regions? Key areas of cost variances such as patient population, project management and grants Methods for better management of accruals and contracts for global studies
Also at the conference, BeVard will facilitate the break-out session, "Methodologies and Processes for Accurately Forecasting Costs for Global Clinical Trials." She will foster an interactive dialogue among attendees regarding forecasting best practices for global clinical trials, including:
What forecasting methods are working? What methods are not working? What industry strategies are being used to handle accruals? How do you manage a clinical budget that is a moving target? What processes do you have in place for accurately forecasting the unknown and planning for unexpected events?
Lucas brings more than 15 years of experience in the pharmaceutical and biotech industry to the conference, with extensive experience in clinical trial budgeting and contract management. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis®. At ICOS, Lucas was responsible for establishing best practices in the outsourcing, management, drafting and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment.
BeVard offers 20 years of industry experience to conference attendees, with an extensive background in clinical trial planning. Prior to joining ClearTrial, she was Executive Director, Clinical Research for the Physician Alliance for Clinical Research (PACR), formerly part of HealthSouth. BeVard also served as Senior Director of Clinical Operations at Otsuka Maryland Research Institute, where she was responsible for the direction, strategy and execution of global clinical trial operations.
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www. cleartrial. com (http://www. cleartrial. com).
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.
# # #